Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Drug Therapy × Tumor-Agnostic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 22 Gastrointestinal 21 Lymphoid 13 Breast 12 Head & Neck 10 Other hematologic neoplasm 8 Gynecologic 6 CNS 6 Genitourinary 5 Dermatologic 5 Sarcoma 3 Other solid neoplasm 2 Tumor-Agnostic 1 Other 1 Myeloid 1 Classical hematology 1

Conditions

Interventions

Paclitaxel 25 Carboplatin 25 pembrolizumab 20 Gemcitabine 20 Nivolumab 17 Cisplatin 15 Bevacizumab 13 Erlotinib Hydrochloride 12 Pemetrexed 11 Fluorouracil 11 Capecitabine 11 Irinotecan 10 Ipilimumab 10 Docetaxel 10 130-nm albumin-bound paclitaxel 9 eribulin 8 Leucovorin 8 Everolimus 8 BI 6727 8 Albumin-Bound Paclitaxel 8 olaparib 7 Oxaliplatin 7 Cyclophosphamide 7 Afatinib 7 lenvatinib 6 avelumab 6 Trastuzumab 6 Radiotherapy 6 Magnetic Resonance Spectroscopy 6 abemaciclib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02004262 2018-06-04

ECLIPSE

Aduro Biotech, Inc.

Phase 2 Completed

303 enrolled 15 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡